S&P/ASX 200 Index (ASX: XJO) shares are down 0.7% to 8,726.2 points on Thursday.
Here at The Fool, we've been super busy analysing the market's performance over FY26.
You might like to check out the 13 ASX 200 shares that doubled (or better) in value last year.
Or the best and worst-performing ASX 200 sectors. Or the No. 1 stock for capital growth in each sector.
In this article, we look ahead to FY27.
Experts reckon these ASX 200 shares could be in for an exceptional period of growth in the new financial year.
Here's why.
Image source: Getty Images
Mesoblast Ltd (ASX: MSB)
The Mesoblast share price rose by a very respectable 18% in FY26 to finish at $1.96 on 30 June.
Bell Potter reiterated its speculative buy rating last week with an unchanged target of $4.45.
This implies the Mesoblast share price could more than double over the next 12 months.
The broker said:
The key overhang on the stock remains clinical trial risk with three massive valuation events over the next 18 months being adult GvHD, back pain and the BLA approval for the first indication in HF.
None of these are priced in.
The broker added:
The recent clinical trial fail by Cynata and its MSC in adult GvHD highlights yet again the risks involved in drug development.
MSB will shortly enrol the first of 180 patients in its randomised, controlled, double blind label expansion study for Ryoncil, also in adult GvHD, albeit with risk of failure mitigated by numerous factors.
These factors include a tried and tested potency assay, more aggressive dose (up to 300% higher than the Cynata product) and a 2nd line patient population that has progressed following steroid therapy.
Judo Capital Holdings Ltd (ASX: JDO)
The Judo share price fell 40% in FY26 to finish at 94 cents.
Judo was smashed in the final month of FY26 after downgrading its profit guidance.
Morgans renewed its buy rating on the ASX 200 bank share with a drastic cut to its price target, which is now $1.47.
This implies the broker is confident of a strong bounce back of at least 55% over the next year.
The share price drawdown was vicious (particularly considering the decline that had already occurred since February).
While the earnings growth outlook has moderated, we still forecast c.30% EPS growth across both FY26 and FY27 with the stock now trading on a c.6.8x PER (FY27F) and 0.6x P:BV (end-FY26).
A significant risk premium or probability of failure has been priced into the stock. BUY.
Zip Co Ltd (ASX: ZIP)
The Zip share price rose 5.5% to close out FY26 at $3.24 on 30 June.
Jonathon Higgins from United Capital Partners (UCPS) says Zip shares are a buy for FY27.
Higgins is impressed with the buy now, pay later company's turnaround.
In a note, Higgins said Zip was on track to report annual cash earnings of more than $260 million just three years after a $50 million loss.
Higgins says the market is underappreciating Zip's cost discipline and its growth prospects in the US.
UCPS has a 12-month target of $4.85. This implies a possible 50% upside over the next year.
Higgins said:
Sustainable earnings momentum against structural growth is hard to find on the ASX currently.
